リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「The baseline recurrence risk of patients with intermediate-risk cervical cancer.」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

The baseline recurrence risk of patients with intermediate-risk cervical cancer.

YONEOKA Yutaka 0000-0002-8255-6293 KOBAYASHI-KATO Mayumi TANASE Yasuhito UNO Masaya ISHIKAWA Mitsuya MURAKAMI Takashi 20240666 0000-0002-0250-0856 KATO Tomoyasu 滋賀医科大学

2021.03

概要

Objective:
This study aimed to investigate the prognosis of patients with intermediate-risk cervical cancer and to evaluate the necessity of adjuvant therapy.
Methods:
We conducted a retrospective chart review of patients with stage IB-II cervical cancer who underwent type III radical hysterectomy with pelvic lymphadenectomy between 2008 and 2017. In our institution, radical hysterectomy is performed as an open surgery and not as a minimally invasive surgery, and adjuvant therapy is not administered to patients with intermediate-risk cervical cancer. The intermediate-risk group included patients with 2 or more of the following factors: tumor size >4 cm, stromal invasion >1/2, and lymphovascular stromal invasion. Intermediaterisk patients with squamous cell carcinoma were included in the I-SCC group, whereas those with endocervical adenocarcinoma, usual type, or adenosquamous carcinoma were included in the I-Adeno group.
Results:
There were 34 and 18 patients in the I-SCC and I-Adeno groups, respectively. The 5-year recurrence-free survival (RFS) and overall survival rates in the I-SCC group were 90.5% (95% confidence interval [CI], 85.3-95.7%) and 100% (95% CI, 100%), respectively, whereas those in the I-Adeno group were 54.9% (95% CI, 42.0-67.9%) and 76.1% (95% CI, 63.7-88.4%), respectively. Multivariate analysis revealed that endocervical adenocarcinoma, usual type, or adenosquamous carcinoma, and tumor size >4 cm had worse RFS.
Conclusion:
The I-SCC group had good prognosis without adjuvant therapy; therefore, adjuvant therapy may be omitted in these patients. In contrast, the I-Adeno group had poor prognosis without adjuvant therapy; therefore, adjuvant therapy should be considered in their treatment.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation

therapy versus no further therapy in selected patients

with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic

Oncology Group study. Gynecol Oncol 1999;73:177-83.

2. Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz

232

SS, Muderspach LI, et al. A phase III randomized trial of

postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol

Phys 2006;65:169-76.

3. Cibula D, Abu-Rustum NR, Fischerova D, Pather S, Lavigne K, Slama J, et al. Surgical treatment of “intermediate risk” lymph node negative cervical cancer patients

without adjuvant radiotherapy - A retrospective cohort

study and review of the literature. Gynecol Oncol

2018;151:438-43.

4. Nakamura K, Kitahara Y, Satoh T, Takei Y, Takano M,

Nagao S, et al. Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical

hysterectomy in FIGO stage IB1 cervical cancer patients

with intermediate risk factors (GOTIC study). World J

Surg Oncol 2016;14:173.

5. N ational Comprehensive Cancer Network (NCCN).

NCCN Clinical Practice Guidelines in Oncology. Cervical

cancer version 2.2020 [Internet]. Plymouth Meeting, PA:

NCCN; 2020 [cited 2020 Oct 2]. Available from: https://

www.nccn.org/professionals/physician_gls/pdf/cervical.

pdf.

6. Ebina Y, Mikami M, Nagase S, Tabata T, Kaneuchi M,

Tashiro H, et al. Japan Society of Gynecologic Oncology

guidelines 2017 for the treatment of uterine cervical

cancer. Int J Clin Oncol 2019;24:1-19.

7. Ryu SY, Kim MH, Nam BH, Lee TS, Song ES, Park CY, et

al. Intermediate-risk grouping of cervical cancer patients

treated with radical hysterectomy: a Korean Gynecologic

Oncology Group study. Br J Cancer 2014;110:278-85.

8. Machida H, Matsuo K, Furusawa A, Kita T, Kitagawa

R, Mikami M. Profile of treatment-related complications in women with clinical stage IB-IIB cervical cancer: a nationwide cohort study in Japan. PLoS One

2019;14:e0210125.

9. Jung PS, Kim DY, Lee SW, Park JY, Suh DS, Kim JH, et al.

Clinical role of adjuvant chemotherapy after radical hysterectomy for FIGO stage IB-IIA cervical cancer: comparison with adjuvant RT/CCRT using inverse-probability-oftreatment weighting. PLoS One 2015;10:e0132298.

10. Lai CH, Chou HH, Chang CJ, Wang CC, Hsueh S, Huang

YT, et al. Clinical implications of human papillomavirus

genotype in cervical adeno-adenosquamous carcinoma.

Eur J Cancer 2013;49:633-41.

www.ogscience.org

Yutaka Yoneoka, et al. Recurrence risk of patients with cervical cancer

11. Baek MH, Park JY, Kim D, Suh DS, Kim JH, Kim YM, et

al. Comparison of adenocarcinoma and adenosquamous

carcinoma in patients with early-stage cervical cancer

after radical surgery. Gynecol Oncol 2014;135:462-7.

12. Huang YT, Wang CC, Tsai CS, Lai CH, Chang TC, Chou

HH, et al. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated

by radical hysterectomy and adjuvant radiotherapy

or chemoradiotherapy. Int J Radiat Oncol Biol Phys

2012;84:420-7.

13. Noh JM, Park W, Kim YS, Kim JY, Kim HJ, Kim J, et al.

Comparison of clinical outcomes of adenocarcinoma

and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy: a multicenter retrospective study (KROG 1310). Gynecol Oncol 2014;132:618-23.

14. Pan X, Yang W, Wen Z, Li F, Tong L, Tang W. Does adenocarcinoma have a worse prognosis than squamous

www.ogscience.org

cell carcinoma in patients with cervical cancer? A realworld study with a propensity score matching analysis. J

Gynecol Oncol 2020;31:e80.

15. Matsuo K, Shimada M, Yokota H, Satoh T, Katabuchi H,

Kodama S, et al. Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer.

Oncotarget 2017;8:106866-75.

16. Lee KB, Lee JM, Ki KD, Lee SK, Park CY, Ha SY. Comparison of adjuvant chemotherapy and radiation in patients

with intermediate risk factors after radical surgery in

FIGO stage IB-IIA cervical cancer. Int J Gynecol Cancer

2008;18:1027-31.

17. Shimada M, Nishimura R, Hatae M, Hiura M, Takehara K,

Tase T, et al. Comparison of adjuvant chemotherapy and

radiotherapy in patients with cervical adenocarcinoma of

the uterus after radical hysterectomy: SGSG/TGCU Inter

group surveillance. Eur J Gynaecol Oncol 2013;34:425-8.

233

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る